[{"address1": "221 Crescent Street", "address2": "Building 17 Suite 102b", "city": "Waltham", "state": "MA", "zip": "02453", "country": "United States", "phone": "650-394-5230", "website": "https://www.apogeetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Thomas Henderson M.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 1171208, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jane Pritchett V. Henderson", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 843643, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Carl Linden Dambkowski M.D.", "age": 37, "title": "Chief Medical Officer", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 870833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Noel  Kurdi", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Batters J.D.", "age": 47, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  Cox", "title": "VP & Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rebecca  Dabora Ph.D.", "age": 63, "title": "Chief Development Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Aspden-Curran", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Drew  Badger Ph.D.", "title": "Senior VP and Head of Regulatory Affairs & Toxicology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Monica  Forbes", "age": 47, "title": "Senior Vice President of Finance", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 46.95, "open": 47.26, "dayLow": 46.09, "dayHigh": 48.58, "regularMarketPreviousClose": 46.95, "regularMarketOpen": 47.26, "regularMarketDayLow": 46.09, "regularMarketDayHigh": 48.58, "forwardPE": -13.400001, "volume": 291492, "regularMarketVolume": 291492, "averageVolume": 445646, "averageVolume10days": 334850, "averageDailyVolume10Day": 334850, "bid": 47.9, "ask": 48.47, "bidSize": 100, "askSize": 100, "marketCap": 2734291456, "fiftyTwoWeekLow": 14.19, "fiftyTwoWeekHigh": 72.29, "fiftyDayAverage": 45.2173, "twoHundredDayAverage": 42.41665, "currency": "USD", "enterpriseValue": 2073758848, "floatShares": 29105411, "sharesOutstanding": 43194300, "sharesShort": 8185424, "sharesShortPriorMonth": 8612212, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1444, "heldPercentInsiders": 0.11417, "heldPercentInstitutions": 1.22843, "shortRatio": 21.5, "shortPercentOfFloat": 0.21290001, "impliedSharesOutstanding": 59012200, "bookValue": 13.229, "priceToBook": 3.6465342, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -118485000, "trailingEps": -2.09, "forwardEps": -3.6, "52WeekChange": 0.9877223, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "APGE", "underlyingSymbol": "APGE", "shortName": "Apogee Therapeutics, Inc.", "longName": "Apogee Therapeutics, Inc.", "firstTradeDateEpochUtc": 1689341400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a31551ee-fb27-3439-a3c7-bbfae7df46cb", "messageBoardId": "finmb_1816591253", "gmtOffSetMilliseconds": -14400000, "currentPrice": 48.24, "targetHighPrice": 95.0, "targetLowPrice": 75.0, "targetMeanPrice": 84.83, "targetMedianPrice": 84.0, "recommendationMean": 1.1, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 676227968, "totalCashPerShare": 11.562, "totalDebt": 4083000, "quickRatio": 27.47, "currentRatio": 27.698, "debtToEquity": 0.528, "returnOnAssets": -0.19296, "returnOnEquity": -0.26725, "freeCashflow": -71462872, "operatingCashflow": -110570000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]